By Katherine Hamilton
Soleno Therapeutics gained approval from the Food and Drug Administration for its hyperphagia drug.
The biopharmaceutical company focused on treating patients with rare diseases said Wednesday it got approval for Vykat XR, which is intended to treat hyperphagia in adults and children over four years old with Prader-Willi syndrome.
Prader-Willi syndrome is a genetic disorder. A hallmark of the disease is hyperphagia, an intense and persistent sense of hunger.
Soleno expects the drug to be available in April, it said.
The approval was based on a study and safety data from a comprehensive clinical development program.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 26, 2025 17:28 ET (21:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。